Nilotinib
别名: AMN-107
中文名称:尼洛替尼
目录号:S1033 Purity: 99.89%
Nilotinib是一种特异性BCR-ABL抑制剂,在小鼠骨髓祖细胞中IC50低于30 nM。Nilotinib (AMN-107)可通过激活AMPK来诱导自噬。
CAS: 641571-10-0
客户使用Selleck的Nilotinib发表文献147篇
- Mol Cancer, 2023 10.1186/s12943-023-01837-4
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Nat Cancer, 2022 3(1):90-107
- Cancer Cell, 2021 S1535-6108(21)00659-0
- Blood, 2020 8 pii: blood
- Cancer Cell, 2019 36(4):431-443
- Nat Cell Biol, 2019 21(6):778-790
- Nature, 2016 534(7607):341-6
- Cancer Discov, 2016 6(11):1248-1257
- Nat Commun, 2024 15(1):651
- Nat Commun, 2024 15(1):2089
- Elife, 2024 12RP92324
- EMBO Rep, 2024 10.1038/s44319-024-00227-1
- Int J Mol Sci, 2024 25(5)2956
- Cancers (Basel), 2024 16(7)1288
- Drug Dev Res, 2024 85(5):e22232
- bioRxiv, 2024 2024.06.06.597767
- NPJ Precis Oncol, 2023 7(1):132
- iScience, 2023 26(4):106309
- Cancers (Basel), 2023 15(3)995
- Cell Rep Methods, 2023 3(4):100440
- bioRxiv, 2023 2023.01.19.524758
- Res Sq, 2023 rs.3.rs-3049913
- bioRxiv, 2023 2023.12.20.572566
- Cell Reports Methods, 2023 10.1016/j.crmeth.2023.100440
- Cell Rep Med, 2022 3(1):100492
- Cancer Res, 2022 82-15:2777-2791
- iScience, 2022 25(10):105182
- J Pers Med, 2022 12(2)258
- Pharmaceuticals (Basel), 2022 15(9)1111
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- J Pharm Sci, 2022 111(8):2180-2190
- Cancer Res, 2021 canres.1222.2021
- EMBO Mol Med, 2021 e11814
- Cell Rep, 2021 35(1):108940
- Mol Metab, 2021 55:101410
- Biochem Pharmacol, 2021 190:114658
- Int Immunopharmacol, 2021 99:108025
- J Mol Biol, 2021 434(2):167349
- Cancers (Basel), 2021 13(21)5543
- Cancers (Basel), 2021 13(7)1693
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Drug Metab Dispos, 2021 49(1):53-61
- Acta Biochim Biophys Sin (Shanghai), 2021 gmab117
- Ann Hematol, 2021 10.1007/s00277-020-04357-z
- Mol Cell, 2020 9 pii: S1097-2765(20)30189-1
- Genome Med, 2020 18;12(1):17
- Cell Rep, 2020 24;30(12):3951-3963 e4
- PLoS Pathog, 2020 16(1):e1008261
- Commun Biol, 2020 3(1):18
- Cancer Cell Int, 2020 19;20:58
- Cancers (Basel), 2020 25;12(5)
- Cancers (Basel), 2020 13;12(2) pii: E436
- FASEB J, 2020 34(3):3773-3791
- Neoplasia, 2020 22(10):470-483
- Front Oncol, 2020 12;10:696
- Sci Rep, 2020 10(1):19723
- J Biomol Struct Dyn, 2020 1-14
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Mol Genet, 2020 ddaa177
- Sci Adv, 2020 6(40)eaba6584
- J Clin Invest, 2019 129(3):1167-1179
- Elife, 2019 8
- Cells, 2019 8(5)
- Front Pharmacol, 2019 10:462
- Mol Cell Biol, 2019 39(14)
- Mol Pharm, 2019 16(5):2069-2082
- Drug Des Devel Ther, 2019 13:4225-4238
- Sci Rep, 2019 9(1):1897
- PLoS One, 2019 14(9):e0214901
- Drugs R D, 2019 19(2):149-166
- Prostate, 2019 79(3):259-264
- Leuk Res, 2019 78:3-11
- Exp Hematol, 2019 77:36-40.e2
- Leuk Lymphoma, 2019 60(1):189-199
- Anticancer Res, 2019 39(7):3785-3793
- Sci Transl Med, 2018 10(427)
- Nat Commun, 2018 9(1):4583
- Arthritis Rheumatol, 2018 70(11):1866-1878
- Hemasphere, 2018 2(3):e41
- Biochem Pharmacol, 2018 156:248-264
- Cancer Sci, 2018 109(11):3591-3601
- Int J Oncol, 2018 52(6):2061-2068
- J Neurol Sci, 2018 391:90-99
- Pigment Cell Melanoma Res, 2018 31(2):253-266
- J Pharm Biomed Anal, 2018 150:112-120
- Cell Adh Migr, 2018 12(4):335-347
- BMC Pharmacol Toxicol, 2018 19(1):80
- Leuk Res, 2018 64:34-41
- Nat Commun, 2017 1;8(1):1232
- Leukemia, 2017 31(5):1253-1254
- Pharmacol Res, 2017 121:184-193
- Elife, 2017 6
- Arch Toxicol, 2017 91(8):2921-2938
- Mol Cancer Ther, 2017 16(9):1729-1738
- Mol Cancer Ther, 2017 16(4):671-680
- Oncotarget, 2017 8(14):23213-23227
- Oncotarget, 2017 8(27):43662-43677
- Cytokine, 2017 90:73-79
- J Appl Toxicol, 2017 37(3):382-390
- SLAS Discov, 2017 22(7):915-922
- Leuk Lymphoma, 2017 58(6):1455-1467
- Leuk Lymphoma, 2017 58(8):1903-1913
- Ther Drug Monit, 2017 39(3):252-262
- J Pharmacol Toxicol Methods, 2017 90:39-47
- Leukemia, 2016 30(6):1273-81
- Acta Biomater, 2016 39:12-24
- Cell Mol Life Sci, 2016 73(9):1927-37
- Oncotarget, 2016 7(29):45916-45925
- Oncotarget, 2016
- Oncotarget, 2016 7(47):78083-78094
- Oncotarget, 2016 7(18):24908-27
- Biochim Biophys Acta, 2016 1862(11):2158-2167
- J Neurochem, 2016 139(4):610-623
- PLoS One, 2016 11(8):e0161415
- PLoS One, 2016 11(10):e0164895
- Nat Commun, 2015 6:7002
- Cell Death Dis, 2015 6:e1767
- Sci Rep, 2015 5:9775
- Neuroscience, 2015 304:316-27
- Leuk Res, 2015 10.1016/j.leukres.2015.08.007
- Mol Neurodegener, 2014 9:46
- Elife, 2014 3:e02523
- Thrombo Res, 2014 135(1):155-60
- Int J Oncol, 2014 44(5):1634-42
- Int J Oncol, 2014 45(5):2167-75
- Stem Cells, 2014 32(9):2324-37
- Antimicrob Agents Chemother, 2014 58(5):2598-607
- Molecules, 2014 19(3):3356-75
- Drug Metab Dispos, 2014 42(11):1851-7
- J Pharm Biomed Anal, 2014 94:125-31
- Pharmacogenet Genomics, 2014 24(1):52-61
- Oncoscience, 2014 1(1):57-68
- J Mol Med, 2013 10.1007/s00109-013-1112-3
- Sci Rep, 2013 3:2102
- Pigment Cell Melanoma Res, 2013 26(4):518-26
- Cell Cycle, 2013 12(18):2978-91
- Pharmgenomics Pers Med, 2013 6:63-72
- Leuk Lymphoma, 2013 54(2):342-52
- University of Heidelberg, 2013 Larissa Daniela
- Leuk Res, 2012 37(2):183-9
- Leuk Res, 2012 36(10):1311-4
- FASEB J, 2011 25(10):3661-73
- Methods Mol Biol, 2010 661:107-22
化学信息&溶解度
分子量 | 529.52 |
分子式 | C28H22F3N7O |
CAS号 | 641571-10-0 |
Smiles | CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 35 mg/mL ( 66.09 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 36 mg/mL ( 67.98 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 50 mg/mL ( 94.42 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 13 mg/mL ( 24.55 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
40%PEG300
5%Tween80
53%ddH2O
浓度:2mg/ml
(3.78mM)
操作示例:以 1 mL 工作液为例,取20 μL 100mg/ml的澄清DMSO储备液加到400 μL PEG300中,混合均匀使其澄清;向上述体系中加入50 μL Tween80,混合均匀使其澄清;然后继续加入530 μL ddH2O定容至1mL。工作液请现配现用!
|
|
4%DMSO
30%PEG300
5%Tween80
61%ddH2O
浓度:3mg/ml
(5.67mM)
操作示例:以 1 mL 工作液为例,取40μL75mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入610μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。